Key points are not available for this paper at this time.
The vaccine developed using the epizootic topical strain is stable, harmless, immunogenic, and effective when challenged with a virulent ND virus strain at a dose of 105 EID50/mL.
Akmyrzaev et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: